News & Updates

Have you got your "Eye on AAO?" Download the 2017 e-bulletins here

25 Jul 2024

The latest research, clinical data and innovations in ophthalmology were presented at the 2017 Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, USA, held on 11−14 November 2017. As in previous years, an international panel of renowned ophthalmologists were supported by Pfizer to attend the meeting and contribute articles to create the Eye on AAO 2017 e-Bulletins. Delivered immediately after each meeting day, and developed with full editorial independence, these e-bulletins feature conference highlights of the latest research, hot topics in ophthalmology and their relevance to the Asia Pacific region.

The e-Bulletins are now collected together and available for download from this page; they are sure to be of significant interest to those seeking the latest advances in ophthalmology.

Have you got your "Eye on AAO?" Download the 2017 e-bulletins here

25 Jul 2024

Special Reports on Trastuzumab Deruxtecan

25 Jul 2024

Discover the latest advancements in cancer treatment with our collection of articles and videos on trastuzumab deruxtecan, a promising targeted therapy changing the landscape for patients with HER2-positive cancers.

Special Reports on Trastuzumab Deruxtecan

25 Jul 2024

Improving outcomes with a soluble guanylate cyclase stimulator in patients with worsening HF

21 May 2024 by

Although guideline-directed medical therapies (GDMTs) for heart failure (HF) with reduced ejection fraction (HFrEF) are effective in reducing risks of mortality and hospitalization for HF (HHF), the clinical burden of HF remains high. At a recent scientific symposium, Dr Yuya Matsue of Juntendo University Graduate School of Medicine in Japan discussed strategies of tackling worsening HF (WHF) to improve patient outcomes and presented a case study of vericiguat in HFrEF.

Improving outcomes with a soluble guanylate cyclase stimulator in patients with worsening HF

21 May 2024

Ultra-long-acting basal insulin optimizes diabetes management

21 May 2024 by

In an interview with MIMS Doctor, Dr Ka-Yuen Lock, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, discussed management of diabetes mellitus (DM), including use of ultra-long-acting insulin, in optimizing glycaemic control. She also shared a case study illustrating improvements in glucose variability and patient’s satisfaction with insulin degludec (IDeg) in type 1 DM (T1DM).

Ultra-long-acting basal insulin optimizes diabetes management

21 May 2024

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

16 May 2024 by

Immunotherapy (IO) has become part of standard care for early-stage non-small-cell lung cancer (NSCLC), necessitating a multidisciplinary approach for optimum treatment. At a symposium conducted during the Hong Kong Thoracic Society and CHEST Autumn Respiratory Seminar (HKTS/CHEST ARS) 2023, Mr Naveed Alam, Consultant Thoracic Surgeon at St. Vincent Hospital in Melbourne, Australia, shared promising results of the IMpower010 trial of adjuvant atezolizumab, emphasized the importance of early involvement of multidisciplinary teams (MDTs) in patient care, and discussed surgeons’ concerns regarding neoadjuvant IO, including high surgical attrition rate, fibrosis, and adhesions.

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

16 May 2024

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

16 May 2024 by

An 81-year-old homebound, obese (BMI, 31 kg/m²) female complained of dyspnoea on exertion and exercise intolerance in 2023. The patient often needed to stop after walking for a distance of two blocks or climbing eight steps of stairs (New York Heart Association [NYHA] functional class II), which limited her daily and social activities.

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

16 May 2024

Long-acting injectable ART offers better QoL for PLHIV

13 May 2024 by

The focus of HIV care has shifted beyond viral suppression towards addressing the holistic needs of people living with HIV (PLHIV) as advances in HIV treatment have considerably extended the lifespan of these patients. At a scientific meeting organized by the Hong Kong Society for HIV Medicine, Dr Chia-Jui Yang of the Department of Internal Medicine, Far Eastern Memorial Hospital (FEMH), Taipei, Taiwan, discussed the importance of implementing patient-reported outcome measures (PROMs) to improve HIV care. Dr Beng Eu of the Prahran Market Clinic, Melbourne, Australia, highlighted a long-acting (LA) antiretroviral therapy (ART) regimen comprising 2-monthly injectable cabotegravir (Vocabria, GlaxoSmithKline) plus rilpivirine as a viable alternative to oral HIV treatment for potentially improving the overall quality of life (QoL) of PLHIV.

Long-acting injectable ART offers better QoL for PLHIV

13 May 2024

Multimodality treatment of early-stage NSCLC: Oncologist’s and surgeon’s perspectives

10 May 2024 by

Positive results of (neo)adjuvant immunotherapy (IO) trials have enabled earlier use of multimodality treatment in non-small-cell lung cancer (NSCLC), which was previously reserved for more advanced disease. At a recent local symposium, oncology and surgery experts discussed latest treatment advances (eg, the IMpower010 trial of adjuvant atezolizumab), redefined unresectability in early-stage disease, highlighted expanded opportunities of cure, and explored hidden costs of neoadjuvant IO.

Multimodality treatment of early-stage NSCLC: Oncologist’s and surgeon’s perspectives

10 May 2024

NMDA receptor antagonist use in a patient with treatment-resistant depression and comorbid PTSD

30 Apr 2024 by

This is the case of a young female professional who was sexually assaulted by her older brother when she was in primary school. The patient had not developed diagnosable psychiatric disorders until April 2023, when exposure of the childhood traumatic event triggered moderate depression (Beck Depression Inventory [BDI] score, 20) and mild anxiety (Beck Anxiety Inventory [BAI] score, 12) as well as severe post-traumatic stress disorder (PTSD) with full-blown symptoms, including flashbacks, insomnia and nightmares every night, anhedonia, dissociation (2–3 times weekly) and conversion symptoms (paralysis) on her right hand and left leg. She withdrew not only from the perpetrator, but also from other family members. She had crying spells, separation anxiety with friends, and decreased work performance due to slow psychomotor speed and poor concentration.

NMDA receptor antagonist use in a patient with treatment-resistant depression and comorbid PTSD

30 Apr 2024

Special Reports on Trastuzumab Deruxtecan

29 Apr 2024

Special Reports on Trastuzumab Deruxtecan

29 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Have you got your "Eye on AAO?" Download the 2017 e-bulletins here

Have you got your "Eye on AAO?" Download the 2017 e-bulletins here

Special Reports on Trastuzumab Deruxtecan

Special Reports on Trastuzumab Deruxtecan

Improving outcomes with a soluble guanylate cyclase stimulator in patients with worsening HF

Improving outcomes with a soluble guanylate cyclase stimulator in patients with worsening HF

Ultra-long-acting basal insulin optimizes diabetes management

Ultra-long-acting basal insulin optimizes diabetes management

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

Long-acting injectable ART offers better QoL for PLHIV

Long-acting injectable ART offers better QoL for PLHIV

Multimodality treatment of early-stage NSCLC: Oncologist’s and surgeon’s perspectives

Multimodality treatment of early-stage NSCLC: Oncologist’s and surgeon’s perspectives

NMDA receptor antagonist use in a patient with treatment-resistant depression and comorbid PTSD

NMDA receptor antagonist use in a patient with treatment-resistant depression and comorbid PTSD

Special Reports on Trastuzumab Deruxtecan

Special Reports on Trastuzumab Deruxtecan